DF Group enters blood plasma market
|
EQS-News: DF Deutsche Forfait AG
/ Key word(s): Takeover
Cologne, 30 April 2025 – The newly founded Deutsche Blutplasma HP GmbH, a wholly owned subsidiary of the intermediate holding company DF Health & Pharma Holding GmbH of DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG), signed a purchase agreement for the assets of the insolvent Ruhr-Plasma-Zentrum Bochum GmbH. DF Group is thus continuing its announced M&A strategy with targeted investments in the food and pharmaceutical sectors and is tapping into an extremely lucrative business segment by entering the field of blood plasma collection. Human blood plasma is needed in the pharmaceutical industry to produce various vital medicines such as blood coagulants and immunoglobulins. The global market for blood plasma derivatives is estimated to reach a volume of over 50 billion US dollars in 2024. According to the Federal Ministry of Health, around 15,000 blood and plasma donations are needed every day in Germany alone. A person in this country is allowed to donate plasma up to 60 times a year - in return for a legally permissible expense allowance. ‘The Ruhr-Plasma-Zentrum Bochum GmbH has developed into a permanent institution for plasma donors in Bochum over more than 30 years and is centrally located directly at the main railway station - Deutsche Blutsplasma HP GmbH would like to continue this success story,’ explains Management Board member Hans-Joachim von Wartenberg on the occasion of the completed asset deal. ‘The collection of blood plasma is fundamentally a very profitable business, and the company's operating business with a loyal base of stem donors has also developed positively in the past. We will now appoint a new management team that will systematically drive forward the expansion of business activities and, in particular, significantly strengthen marketing, which has been neglected to date.’ With this acquisition, DF Group has successfully completed its second M&A transaction within ten months. The new location in Bochum will serve as a starting point for the further expansion of the blood plasma division. It is conceivable that the company will open its own new stores as well as potentially taking over other locations throughout Germany or in neighbouring countries. The purchase will take effect on 1 May 2025 and is subject to the approval of the creditors' meeting. About DF Group DF Group is a finance company with the business units Foreign Trade Finance, Proprietary Trading and M&A. The industry focus is on the food, beverages, pharmaceutical and healthcare sectors. As a specialist in foreign trade financing with a regional focus on the Middle East, Europe and Central Asia, we offer our clients customised product solutions - based on many years of experience, a strong network and comprehensive compliance expertise. M&A activities have also been an integral part of DF Group's business model since 2024. Contact DF Deutsche Forfait AG Guido Janzen
30.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | DF Deutsche Forfait AG |
| Gustav-Heinemann-Ufer 56 | |
| 50968 Köln | |
| Germany | |
| Phone: | +49 221 97376 - 0 |
| E-mail: | dfag@dfag.de |
| Internet: | www.dfag.de |
| ISIN: | DE000A2AA204, DE000A1R1CC4, |
| WKN: | A2AA20, A1R1CC |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2126836 |
| End of News | EQS News Service |
|
|
2126836 30.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.